NeuroMetrix, Inc. (NURO)
| Market Cap | 13.36M |
| Revenue (ttm) | 7.38M |
| Net Income (ttm) | -2.09M |
| Shares Out | 3.78M |
| EPS (ttm) | -0.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 3 |
| Last Price | $3.41 |
| Previous Close | $3.70 |
| Change ($) | -0.29 |
| Change (%) | -7.84% |
| Day's Open | 3.70 |
| Day's Range | 3.39 - 3.99 |
| Day's Volume | 554,737 |
| 52-Week Range | 0.81 - 6.20 |
NeuroMetrix, Inc. (NURO) CEO Dr. Shai Gozani on Q4 2020 Results - Earnings Call Transcript
WOBURN, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and year ended December 31, 2020. The Company...
WOBURN, Mass., Jan. 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2020 fourth quarter and full year financial results before the open...
NeuroMetrix (NASDAQ: NURO) is currently up 45.17% to a price of $3.04. The stock's volume is currently 62.04 million, which is roughly 32668.92% of its recent 30-day volume average of 189.91 t...
NeuroMetrix (NURO) stock is on the rise Tuesday with heavy trading despite a lack of news concerning the medical device company. The post NURO Stock: 10 Things for Potential Investors to Know ...
NeuroMetrix, Inc. (NURO) CEO Dr. Shai Gozani on Q3 2020 Results - Earnings Call Transcript
WOBURN, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2020. The Company is a le...
WOBURN, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 third quarter financial results before the opening of the marke...
Who Will Win The Lucrative Autonomous Vehicles (Robotaxis) Race?
WOBURN, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the launch of the Quell Watch App, now available for download from the Apple App store.
WOBURN, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office will issue on September 22, 2020 U.S. Patent No. ...
WOBURN, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it will present a scientific poster at the PAINWeek 2020 Live Virtual Conference to be ...
WOBURN, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the publication of a large study demonstrating that DPNCheck effectively determines the seve...
WOBURN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell device will be used in an NIH-funded, multi-site randomized controlled trial ...
WOBURN, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) published an infographic on chronic knee pain ( available here ) and provided an update on how Quell technol...
NeuroMetrix's (NURO) CEO Shai Gozani on Q2 2020 Results - Earnings Call Transcript
WOBURN, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended June 30, 2020. The Company is a leadi...
WOBURN, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 second quarter financial results before the opening of the ma...
WOBURN, Mass., July 09, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced expanded distribution in China for DPNCheck, a fast, accurate and quantitative nerve conduct...
WOBURN, Mass., June 25, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it has signed a collaboration agreement with Biomedix to comarket DPNCheck for periphera...
WOBURN, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has launched a marketing initiative focusing on chronic knee pain. This effort incl...
NeuroMetrix, Inc. (NURO) CEO Shai Gozani on Q1 2020 Results - Earnings Call Transcript
WOBURN, Mass., April 16, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that Quell technology has been selected for use in a large, NIH-funded, randomized, pragmat...
WOBURN, Mass., March 11, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today provided an update on its Quell technology commercial strategy and pipeline.
WOBURN, Mass., March 05, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the recent publication of three additional DPNCheck clinical studies. DPNCheck is a point-of...
NeuroMetrix, Inc. (NASDAQ:NURO) Q4 2019 Results Conference Call January 27, 2020 8:00 AM ET
Shares of Common Stock and Certain Warrants Will Begin Trading on a Split-Adjusted Basis on November 19, 2019 Shares of Common Stock and Certain Warrants Will Begin Trading on a Split-Adjusted...
NeuroMetrix's (NURO) CEO Shai Gozani on Q3 2019 Results - Earnings Call Transcript
WOBURN, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2019.
WOBURN, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), a health technology company that develops and commercializes products for the chronic pain and diabetes mark...
NeuroMetrix, Inc. (NURO) CEO Shai Gozani on Q2 2019 Results - Earnings Call Transcript
NeuroMetrix (NURO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeuroMetrix, Inc. (NURO) CEO Shai Gozani on Q1 2019 Results - Earnings Call Transcript
NeuroMetrix (NURO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About NURO
NeuroMetrix, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evalua... [Read more...]
| Industry Medical Instruments & Supplies | Founded 1996 |
| CEO Shai Gozani | Employees 20 |
| Stock Exchange NASDAQ | Ticker Symbol NURO |
Financial Performance
In 2020, NeuroMetrix's revenue was $7.38 million, a decrease of -20.43% compared to the previous year's $9.27 million. Losses were -$2.09 million, -44.55% less than in 2019.